VasQ and A
The FDA has approved VasQ, a new device to reduce fistula failure, for a 2-year clinical trial with 129 patients. The device keeps fistulas from growing too large by providing an external support.
Read the full article » | Posted 08-17-2017
Related Articles
- VenoStent, Inc. is Recruiting Patients for a Clinical Trial of the SelfWrap Posted 10-14-2025
- Diality Treated its First Patient in the Moda-flx Home IDE PRESCRIBE Cinical Trial Posted 10-14-2025
- eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant Posted 09-15-2025
- The First Artificial Kidney Built in Canada has Ties to London: A Revolution in Care for Patients with Kidney Failure Posted 09-15-2025

